| Literature DB >> 33264411 |
Sebastian Köhler1,2, Michael Gargano2,3, Nicolas Matentzoglu2,4,5, Leigh C Carmody2,3, David Lewis-Smith6,7, Nicole A Vasilevsky2,8, Daniel Danis, Ganna Balagura9,10, Gareth Baynam11,12, Amy M Brower13, Tiffany J Callahan14, Christopher G Chute15, Johanna L Est16, Peter D Galer17,18, Shiva Ganesan17,18, Matthias Griese16,19, Matthias Haimel20,21, Julia Pazmandi20,21,22, Marc Hanauer23, Nomi L Harris2,24, Michael J Hartnett13, Maximilian Hastreiter16, Fabian Hauck16,25, Yongqun He26, Tim Jeske16, Hugh Kearney27, Gerhard Kindle28,29, Christoph Klein16, Katrin Knoflach16,19, Roland Krause30, David Lagorce23, Julie A McMurry2,31, Jillian A Miller13, Monica C Munoz-Torres2,31, Rebecca L Peters13, Christina K Rapp16,19, Ana M Rath23, Shahmir A Rind32,33, Avi Z Rosenberg34, Michael M Segal35, Markus G Seidel36, Damian Smedley37, Tomer Talmy38,39, Yarlalu Thomas40, Samuel A Wiafe41, Julie Xian17,42, Zafer Yüksel43, Ingo Helbig44,45, Christopher J Mungall2,24, Melissa A Haendel2,8,31, Peter N Robinson2,3,22.
Abstract
The Human Phenotype Ontology (HPO, https://hpo.jax.org) was launched in 2008 to provide a comprehensive logical standard to describe and computationally analyze phenotypic abnormalities found in human disease. The HPO is now a worldwide standard for phenotype exchange. The HPO has grown steadily since its inception due to considerable contributions from clinical experts and researchers from a diverse range of disciplines. Here, we present recent major extensions of the HPO for neurology, nephrology, immunology, pulmonology, newborn screening, and other areas. For example, the seizure subontology now reflects the International League Against Epilepsy (ILAE) guidelines and these enhancements have already shown clinical validity. We present new efforts to harmonize computational definitions of phenotypic abnormalities across the HPO and multiple phenotype ontologies used for animal models of disease. These efforts will benefit software such as Exomiser by improving the accuracy and scope of cross-species phenotype matching. The computational modeling strategy used by the HPO to define disease entities and phenotypic features and distinguish between them is explained in detail.We also report on recent efforts to translate the HPO into indigenous languages. Finally, we summarize recent advances in the use of HPO in electronic health record systems.Entities:
Mesh:
Year: 2021 PMID: 33264411 PMCID: PMC7778952 DOI: 10.1093/nar/gkaa1043
Source DB: PubMed Journal: Nucleic Acids Res ISSN: 0305-1048 Impact factor: 16.971